T1	p 178 197	diabetic patients :
T2	p 672 733	all , 360 diabetic patients with coronary artery disease were
T3	p 742 746	with
T4	p 2458 2468	patients .
T5	p 2559 2607	diabetic patients with coronary artery disease .
T6	i 119 131	pioglitazone
T7	i 228 240	Pioglitazone
T8	i 451 463	pioglitazone
T9	i 582 594	Pioglitazone
T10	i 628 639	glimepiride
T11	i 747 774	pioglitazone or glimepiride
T12	i 808 820	Pioglitazone
T13	i 1568 1580	pioglitazone
T14	i 1758 1769	glimepiride
T15	i 2356 2368	pioglitazone
T16	o 467 489	atheroma progression .
T17	o 559 567	atheroma
T18	o 934 954	atheroma progression
T19	o 1042 1118	biochemical parameters , percent atheroma volume , and total atheroma volume
T20	o 1207 1337	in high-density lipoprotein cholesterol ( HDL-C ) and reductions in glycated hemoglobin , triglycerides , and C-reactive protein .
T21	o 1396 1437	percent atheroma volume and triglycerides
T22	o 1464 1488	triglyceride/HDL-C ratio
T23	o 1515 1538	and glycated hemoglobin
T24	o 1598 1633	low-density lipoprotein cholesterol
T25	o 1661 1677	apolipoprotein B
T26	o 1709 1727	apolipoprotein A-I
T27	o 1784 1805	atheroma regression ,
T28	o 1818 1829	progression
T29	o 1879 1887	in HDL-C
T30	o 1944 1957	triglycerides
T31	o 1995 2019	triglyceride/HDL-C ratio
T32	o 2067 2089	in glycated hemoglobin
T33	o 2245 2268	percent atheroma volume
T34	o 2286 2307	total atheroma volume
T35	o 2417 2445	delayed atheroma progression